The present disclosure presents systems and methods for administering blood products having a personalized concentration of coagulation factors. One such method includes obtaining measured coagulation factor concentrations from a blood sample of a subject; generating a clotting prediction for the subject based on the measured blood factor concentrations of the subject; determining one or more coagulation factor concentrations to be administered to the subject based on the clotting prediction; iteratively generating a new clotting prediction for the subject based on the determined coagulation factors; iteratively determining additional coagulation factor concentrations to be administered to the subject based on the new clotting prediction until the subject’s coagulation factor concentrations are predicted to equilibrate at a predefined normal range; and/or outputting a recommended set of coagulation factor concentrations to be administered to the subject based on the determined coagulation factor concentrations. Other methods and systems are also provided.

A highly sensitive blood coagulation test reagent that enables determining and evaluating bleeding risk of direct oral anticoagulants (DOACs) and the like accurately in hemorrhagic diseases, and the like are provided. A blood coagulation test reagent containing: an active form of a blood coagulation factor XI (FXIa); and tissue factor (TF). A blood coagulation test method including a step of measuring the amount of thrombin generated by reacting a biological sample as a test specimen with a test reagent containing: 0.5 pM to 1,000 pM of an active form of a blood coagulation factor XI(FXIa); and 1 fM to 1,000 fM of tissue factor.

The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.

Embodiments of the present invention are in the field of blood coagulation diagnostics and relate to a test for establishing an individual's blood coagulation system status based on the amount of in-vitro-generated F1+2 peptide, and to a test kit for use in such a method.

Disclosed is an apparatus for testing blood coagulation indicators, including a blood sample receiving and preprocessing unit, and the blood preprocessing part is configured to remove or neutralize the anticoagulation effect of the artificially added anticoagulant in the blood sample; a reacting unit in which the blood undergoes a clotting process; a blood coagulation indicator analyzing and computing unit which may measure an electrical signal passing through the blood sample during the course of testing to obtain measurement results reflecting a time measurement function; and a result displaying unit. Further disclosed is a method for testing coagulation indicators of a blood sample using the apparatus.

Provided herein are method and kits for identifying thrombus origin based on temporal thrombin activity assay, and use thereof for optimizing post-ischemic event treatment, and further preventing recurrence of secondary ischemic events.

Provided herein are methods for the diagnosis, prognosis, and treatment of thrombosis in subject having or suspected of having systemic lupus erythematosus including determination of a level of platelet-bound complement C4d, C3 level, and one or both of a level of antiphosphatidyl serine/prothrombin complex and/or lupus anticoagulant.

The present invention relates to analytical testing devices comprising fluidic junctions and methods for assaying coagulation in a fluid sample received within the fluidic junctions. For example, the present invention may be directed to a sample analysis cartridge including an inlet chamber, a first conduit comprising a first junction configured to split a biological sample into at least first and second segments, a second conduit comprising a first reagent, a first sensor region, and a first fluidic lock valve, and a third conduit comprising a second reagent, a second sensor region, and a second fluidic lock valve. The sample analysis cartridge further includes a pump configured to push the first segment over the first sensor region to the first fluidic lock valve, and push the second segment over the second sensor region to the second fluidic lock valve.

Described is a sample holder assembly including a functionalized test well wall, which may be used in combination with a light source.

Provided is a reagent for assaying a thrombin-antithrombin complex (TAT) in a blood sample from a subject by latex agglutination assay. The reagent includes a polycation. As a result, TAT complexes can be precisely assayed while circumventing the effect of heparin. The polycation is, for example, hexadimethrine bromide, chitosans, modified dextran, aminodextran, hydroxymethyl cellulose trimethylamine, lysozyme, spermine, spermidine, polylysine, polyarginine, polyornithine, protamine sulfate, hydroxyethyl cellulose trimethylamine, heparin-binding protein, polyallylamine, polyallylamine hydrochloride, poly(diallyl dialkyl amine), polyamideamine, polyamine, polyvinylbenzyltrimethylammonium chloride, polydiallyldimethylammonium chloride, polyethyleneimine, polypropyleneimine, polypropylethyleneimine, polyimidazoline, polyvinylamine, polyvinyl pyridine, poly(acrylamide/methacryloxypropyltrimethylammonium bromide), poly(diaryldimethylammonium chloride/N-isopropylacrylamide), poly(dimethylaminoethyl acrylate/acrylamide), poly(dimethylaminoethyl methacrylate), polydimethylaminoepichlorohydrin, polyethyleneiminoepichlorohydrin, polymethacryloxyethyl-trimethylammonium bromide, hydroxypropylmethacryloyloxyethyl dimethyl ammonium chloride, poly(methyldiethylaminoethylmethacrylate/acrylamide), poly(methyl/guanidine), polymethylvinylpyridinium bromide, poly(vinylpyrrolidone-dimethylaminoethyl methacrylate), or polyvinylmethylpyridinium bromide.